NO20073403L - Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1 - Google Patents
Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1Info
- Publication number
- NO20073403L NO20073403L NO20073403A NO20073403A NO20073403L NO 20073403 L NO20073403 L NO 20073403L NO 20073403 A NO20073403 A NO 20073403A NO 20073403 A NO20073403 A NO 20073403A NO 20073403 L NO20073403 L NO 20073403L
- Authority
- NO
- Norway
- Prior art keywords
- ugt1a1
- atazanavir
- pharmacokinetics
- improve
- drugs metabolized
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 title abstract 2
- 108010019625 Atazanavir Sulfate Proteins 0.000 title abstract 2
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 title abstract 2
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 title abstract 2
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 title abstract 2
- 229960003277 atazanavir Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63294504P | 2004-12-03 | 2004-12-03 | |
| PCT/US2005/043782 WO2006060731A2 (en) | 2004-12-03 | 2005-12-02 | Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073403L true NO20073403L (no) | 2007-08-31 |
Family
ID=36565812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073403A NO20073403L (no) | 2004-12-03 | 2007-07-02 | Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070259894A1 (https=) |
| EP (1) | EP1824957A4 (https=) |
| JP (1) | JP2008521934A (https=) |
| KR (1) | KR20070085702A (https=) |
| CN (1) | CN101068916A (https=) |
| AU (1) | AU2005311672B2 (https=) |
| BR (1) | BRPI0518741A2 (https=) |
| CA (1) | CA2588466A1 (https=) |
| IL (1) | IL183383A0 (https=) |
| MX (1) | MX2007006637A (https=) |
| NO (1) | NO20073403L (https=) |
| NZ (1) | NZ555215A (https=) |
| RU (1) | RU2403066C2 (https=) |
| WO (1) | WO2006060731A2 (https=) |
| ZA (1) | ZA200703989B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7491819B1 (en) | 2004-05-28 | 2009-02-17 | Bristol-Myers Squibb Company | N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| EP1819323B2 (en) | 2004-12-03 | 2023-03-22 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
| EP1904067B2 (en) | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| UA87884C2 (uk) | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| EP2116532B1 (en) | 2007-06-12 | 2011-12-07 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives as HIV protease inhibitors |
| US20100273203A1 (en) * | 2009-04-23 | 2010-10-28 | Board Of Trustees Of The University Of Arkansas | Methods and compositions for detecting metabolites |
| US8410064B2 (en) * | 2009-08-24 | 2013-04-02 | The Board Of Trustees Of The University Of Arkansas | Classical cannabinoid metabolites and methods of use thereof |
| WO2011026112A1 (en) * | 2009-08-31 | 2011-03-03 | The Board Of Trustees Of The University Of Arkansas | Compositions comprising specific ugt inhibitors and methods of use thereof |
| US9649311B2 (en) | 2009-10-26 | 2017-05-16 | Merck Sharp & Dohme Corp. | Solid pharmaceutical compositions containing an integrase inhibitor |
| US8883218B2 (en) * | 2010-03-26 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Anti-cancer nanoparticle compositions and methods of use |
| US9095598B2 (en) | 2010-12-28 | 2015-08-04 | The Board Of Trustees Of The University Of Arkansas | Stilbenoid derivatives and their uses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| PL360944A1 (en) * | 2000-10-12 | 2004-09-20 | Merck & Co, Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| ATE355064T1 (de) * | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| IL161337A0 (en) * | 2001-10-26 | 2004-09-27 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| US20030215462A1 (en) * | 2001-12-21 | 2003-11-20 | Wacher Vincent J. | Use of UGT inhibitors to increase bioavailability |
| NZ540729A (en) * | 2002-12-27 | 2008-03-28 | Angeletti P Ist Richerche Bio | Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors |
| US20040192624A1 (en) * | 2003-03-24 | 2004-09-30 | Kempf Dale J. | Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| EP1904067B2 (en) * | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| EP1819323B2 (en) * | 2004-12-03 | 2023-03-22 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
-
2005
- 2005-12-02 BR BRPI0518741-9A patent/BRPI0518741A2/pt not_active IP Right Cessation
- 2005-12-02 KR KR1020077012547A patent/KR20070085702A/ko not_active Withdrawn
- 2005-12-02 JP JP2007544571A patent/JP2008521934A/ja not_active Withdrawn
- 2005-12-02 CN CNA2005800413696A patent/CN101068916A/zh active Pending
- 2005-12-02 AU AU2005311672A patent/AU2005311672B2/en not_active Ceased
- 2005-12-02 US US11/792,189 patent/US20070259894A1/en not_active Abandoned
- 2005-12-02 WO PCT/US2005/043782 patent/WO2006060731A2/en not_active Ceased
- 2005-12-02 NZ NZ555215A patent/NZ555215A/en not_active IP Right Cessation
- 2005-12-02 EP EP05852867A patent/EP1824957A4/en not_active Withdrawn
- 2005-12-02 CA CA002588466A patent/CA2588466A1/en not_active Abandoned
- 2005-12-02 RU RU2007125130/15A patent/RU2403066C2/ru not_active IP Right Cessation
- 2005-12-02 MX MX2007006637A patent/MX2007006637A/es unknown
-
2007
- 2007-05-17 ZA ZA200703989A patent/ZA200703989B/xx unknown
- 2007-05-24 IL IL183383A patent/IL183383A0/en unknown
- 2007-07-02 NO NO20073403A patent/NO20073403L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008521934A (ja) | 2008-06-26 |
| RU2007125130A (ru) | 2009-01-10 |
| CA2588466A1 (en) | 2006-06-08 |
| KR20070085702A (ko) | 2007-08-27 |
| ZA200703989B (en) | 2008-09-25 |
| BRPI0518741A2 (pt) | 2008-12-02 |
| MX2007006637A (es) | 2007-06-19 |
| EP1824957A2 (en) | 2007-08-29 |
| US20070259894A1 (en) | 2007-11-08 |
| CN101068916A (zh) | 2007-11-07 |
| AU2005311672A1 (en) | 2006-06-08 |
| IL183383A0 (en) | 2007-09-20 |
| WO2006060731A3 (en) | 2006-09-28 |
| NZ555215A (en) | 2010-08-27 |
| RU2403066C2 (ru) | 2010-11-10 |
| EP1824957A4 (en) | 2011-02-09 |
| AU2005311672B2 (en) | 2010-07-22 |
| WO2006060731A2 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073403L (no) | Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1 | |
| Cui et al. | Efficacy and safety of long‐term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| CY1110495T1 (el) | Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα | |
| NO20080827L (no) | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon | |
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| NO20092527L (no) | Prolegemidler, fremgangsmate for fremstilling og anvendelse derav | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| JP2006508953A5 (https=) | ||
| CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
| ID29181A (id) | Kombinasi formoterol dan garam tiotropium | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
| PL2043637T3 (pl) | Sposoby i leki do podawania ibuprofenu | |
| NO20073774L (no) | Terapeutiske forbindelser for intranasal administrering av ketorolac | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| TW200738228A (en) | Neramexane modified release matrix tablet | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| NO341573B1 (no) | Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| NO20055173L (no) | Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel | |
| CY1118263T1 (el) | Φλουρμπιπροφαινη ελεγχομενης εκλυσης και μυοχαλαρωτικοι συνδιασμοι | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| WO2005010022A3 (en) | Agonist polypeptide of receptor for zot and zonulin | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |